Mount Capital’s Moderna MRNA Stock Holding History

Mount Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.1M	Buy	457,900 +62,700	+16%	+$3.24M	12.1%	3
2026 Q1	$20.1M	Buy	+395,200	New	+$18.4M	8.09%	5

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Mount Capital's MRNA Position: Q2 2026 in Review

Mount Capital increased its Moderna (MRNA) stake by 16% in Q2 2026, buying an estimated $3.24M and bringing the position to 457,900 shares worth $32.1M. The position accounts for 12.1% of the portfolio, ranked #3.

Mount Capital first reported a position in MRNA in Q1 2026 and has held it in 2 quarters since. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Mount Capital held 457,900 shares of Moderna worth $32.1M as of Q2 2026.
Mount Capital bought 62,700 Moderna shares in Q2 2026, an estimated $3.24M.
Moderna made up 12.1% of Mount Capital's portfolio in Q2 2026, its #3 holding.
Mount Capital first reported a position in Moderna in Q1 2026 and has held it in 2 quarters since.
784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Mount Capital's 13F filing for Q2 2026, filed 13 Aug 2026.